Cumberland Pharmaceuticals CPIX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$3.29M-363% | -$1.43M+24.9% | -$1.95M-26.8% | -$735.21K+33.3% | $1.25M+166% | ||
| $1.28M+23.7% | $1.04M-30.4% | $1.04M-7.0% | $1.03M-9.3% | $1.03M-10.4% | ||
| $106.84K+44.0% | $172.16K+130% | $81.26K+6.4% | $80.69K+12.1% | $74.21K-5.8% | ||
| $5.17K-3.5% | $7.1K-20.5% | $5.36K-50.0% | $5.36K+10.7% | $5.36K+40.7% | ||
| -$2.68M-121% | $6.51M+1,567% | $113.69K— | -$171.01K-122% | -$1.21M-214% | ||
| -$703.86K+27.2% | $0+100% | -$630.41K— | -$850.8K+20.7% | -$967.4K-467% | ||
| -$1.35M-124% | $8.04M+2,580% | $684.22K— | -$1.42M-10.8% | -$600.04K+7.0% | ||
| -$384.15K-536% | $1.05M— | -$178.94K+70.1% | -$579.65K-165% | -$60.37K+70.6% | ||
| -$202.82K+31.0% | -$129.23K— | -$349.78K+22.0% | $295.31K— | -$293.94K-288% | ||
| -$146.08K— | —— | —— | —— | $0— | ||
| $285.18K0.0% | $285.19K0.0% | $285.18K0.0% | $285.19K0.0% | $285.18K0.0% | ||
| -$225.35K-2.7% | -$173.98K-107% | -$221.68K-2.7% | -$220.95K-2.7% | -$219.49K-2.7% | ||
| -$228.97K-609% | —— | $9.65K+102% | $38.6K+118% | $44.98K+120% | ||
| $387.03K-90.1% | $3.02K— | $187.18K— | $843.8K+199% | $3.9M+282% | ||
| $0-100% | $0-100% | $23.79K+54.7% | $26.49K+269% | $47.63K+14.4% | ||
| $19.16K+5.3% | $43.84K+78.8% | $8.45K-74.0% | $13.91K-64.9% | $18.2K+9.9% | ||
| -$61.17K+95.0% | -$3.07M— | -$690.84K-464% | $0+100% | -$1.23M-2,011% | ||
| $61K-75.2% | $0-100% | $10.44K-89.4% | $7.17K-94.7% | $245.87K-0.7% | ||
| $0-100% | —— | —— | —— | $10.04M+30.3% | ||
| $702.3K+37.4% | $681.74K+46.7% | $376.44K-14.1% | $143.63K-21.4% | $511.13K-19.0% | ||
| -$763.3K+86.2% | -$681.74K— | -$386.88K— | -$150.8K— | -$5.53M-328% | ||
| -$437.45K+84.7% | -$3.75M— | -$890.54K— | —— | -$2.86M-1,359% | ||
| —— | $110.42K-22.4% | $110.42K-22.4% | $110.42K-22.4% | $110.42K-22.4% | ||
| —— | -$881.25-124% | -$881.25-124% | -$881.25-124% | -$881.25-124% | ||
| $5.17K-3.5% | $7.1K-20.5% | $5.36K-50.0% | $5.36K+10.7% | $5.36K+40.7% | ||
| -$228.97K-609% | —— | $9.65K+102% | $38.6K+118% | $44.98K+120% | ||
| —— | -$3.31K— | -$3.31K— | -$3.31K— | -$3.31K— | ||
| -$86.95K-7.1% | —— | $91.46K+16.4% | $121.69K— | -$81.18K-163% | ||
| -$225.35K-2.7% | -$173.98K-107% | -$221.68K-2.7% | -$220.95K-2.7% | -$219.49K-2.7% | ||
| -$202.82K+31.0% | -$129.23K— | -$349.78K+22.0% | $295.31K— | -$293.94K-288% | ||
| -$384.15K-536% | $1.05M— | -$178.94K+70.1% | -$579.65K-165% | -$60.37K+70.6% | ||
| $285.18K0.0% | $285.19K0.0% | $285.18K0.0% | $285.19K0.0% | $285.18K0.0% | ||
| $0-100% | —— | —— | —— | $1.16M— | ||
| $19.16K+5.3% | $43.84K+78.8% | $8.45K-74.0% | $13.91K-64.9% | $18.2K+9.9% | ||
| $42.02K— | —— | —— | —— | $0— | ||
| —— | $500K— | $500K— | $500K— | $500K— | ||
| $0+100% | —— | —— | —— | -$5.27M— | ||
| $0-100% | —— | —— | —— | $10.04M+30.3% | ||
| —— | $15.5+100% | $15.5+100% | $15.5+100% | $15.5+100% | ||
| -$225.35K-2.7% | -$173.98K-107% | -$221.68K-2.7% | -$220.95K-2.7% | -$219.49K-2.7% | ||
| —— | $500K— | $500K— | $500K— | $500K— | ||
| $702.3K+37.4% | $681.74K+46.7% | $376.44K-14.1% | $143.63K-21.4% | $511.13K-19.0% | ||
| —— | $1.18K+792% | $1.18K+792% | $1.18K+792% | $1.18K+792% | ||
| -$146.08K— | —— | —— | —— | $0— | ||
| —— | $209.03K-3.2% | $209.03K-3.2% | $209.03K-3.2% | $209.03K-3.2% | ||
| —— | -$881.25-124% | -$881.25-124% | -$881.25-124% | -$881.25-124% | ||
| $387.03K-89.9% | $3.03K— | $163.39K— | $817.32K+195% | $3.85M+277% | ||
| $387.03K-89.9% | $3.03K— | $163.39K— | $817.32K+195% | $3.85M+277% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cumberland Pharmaceuticals generate?
- Cumberland Pharmaceuticals (CPIX) generated $1.4M in operating cash flow over the trailing twelve months.
- What is Cumberland Pharmaceuticals's free cash flow?
- After $50.3K of capital expenditures, Cumberland Pharmaceuticals's free cash flow was $1.4M over the trailing twelve months, down 23.9% year over year.
- Where does Cumberland Pharmaceuticals's cash flow data come from?
- Every line is extracted from Cumberland Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
